Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

72 BLEOMYCIN
(1996): Epstein E, The Schoch Letter 46, 34 (observation)
(1996): Munn SE+, Br J Dermatol 135, 969
(1994): Toumbis-Ioannou E+, Cleve Clin J Med 61(3), 195
(1993): von Gunten CF+, Cancer 72, 2004
(1992): de Pablo P+, Acta Derm Venereol (Stockh) 72, 465
(1992): Doll DC+, Semin Oncol 19(5), 580
(1992): Gregg LJ, JAmAcadDermatol26, 279
(1992): Hansen SW, Dan Med Bull 39(5), 391 (with cisplatin &
vinblastine)
(1991): Epstein E, JAmAcadDermatol24, 785
(1990): Cortina P+, Dermatologica 180(2), 106
(1990): Hansen SW+, Ann Oncol 1(4), 289
(1989): Hansen SW+, J Clin Oncol 7(7), 940
(1988): Stefenelli T+, Eur Heart J 9(5), 552 (with vinblastine, and
cisplatin)
(1987): Werquin S+, Ann Cardiol Angeiol (Paris) 36(8), 409
(1986): Doll DC+, J Clin Oncol 4(9), 1405
(1986): Dzieza-Lalowicz I+, Pol Tyg Lek 41(7), 218 (with
vinblastine)
(1985): Adoue D+, Ann Dermatol Venereol (French) 112, 151
(1985): Bovenmyer DA, JAmAcadDermatol13, 470
(1985): Epstein E, JAmAcadDermatol13, 468
(1985): McGuire WA+, Med Pediatr Oncol 13(6), 392
(1985): Smith EA+, Arthritis Rheum 28(4), 459
(1985): Vogelzang NJ+, Cancer 56(12), 2765 (with vinblastine &
cisplatin)
(1984): Adoue D+, AnnInternMed100, 770
(1984): Davis TE+, Gynecol Oncol 19(1), 46 (with vinblastine &
cisplatin)
(1984): Snauwaert J+, Dermatologica 169, 172
(1983): Bork A+, Hautarzt (German) 34, 10
(1982): Scheulen ME+, Dtsch Med Wochenschr 107(43), 1640
(with vinblastine)
(1981): Harvey HA+, AnnInternMed94(4 pt 1), 542 (with
vinblastine)
(1981): Kukla LJ+, Arch Dermatol 117, 604
(1980): Paty JG+, J Rheumatol 7(6), 927 (with vinblastine)
Scleroderma
(2005): Lahiri K, Kolkata, India (from Internet) (observation)
(2004): Yamamoto T+, J Invest Dermatol 122(1), 44
(2000): D’Cruz D, Toxicol Lett 112 and 421
(1999): Passiu G+, Clin Rheumatol 18, 422
(1998): Behrens S+, Hautarzt (German) 49, 725
(pseudoscleroderma)
(1997): Komosinska K+, Postepy Hig Med Dosw (Polish) 51, 285
(1994): Marck Y+, Ann Dermatol Venereol (French) 121, 712,
(1992): Kerr LD+, J Rheumatol 19, 294
(1991): Bourgeois P+, Baillieres Clin Rheumatol 5, 13
(1991): Guseva NG, Revmatologiia Mosk (Russian) 1, 33
(1985): Haustein UF+, Int J Dermatol 24, 147
(1984): Rush PJ+, J Rheumatol 11, 262
(1983): Bork K+, Hautarzt (German) 34, 10
(1980): Finch WR+, J Rheumatol 7, 651
Stevens–Johnson syndrome
(1989): Brodsky A+, J Clin Pharmacol 29, 821
(1986): Giaccone G+, Tumori 72, 331
Thickening
Urticaria
Xerosis
Mucosal
Glossitis
(1992): Breathnach SM+, Adverse Drug Reactions and the Skin
Blackwell, Oxford, 292 (passim)
Oral papillomatosis
Oral ulceration
(1992): Breathnach SM+, Adverse Drug Reactions and the Skin
Blackwell, Oxford, 292 (passim)
Stomatitis (>10%)
(1999): Susser WS+, JAmAcadDermatol40(3), 367
(1993): Haerslev T+, Cutis 52, 45
(1990): Siegel RD+, Chest 98, 507
(1983): Bronner AK+, JAmAcadDermatol9, 645
Tongue erosions
Hair
Hair – alopecia (~50%)
(1999): Susser WS+, JAmAcadDermatol40(3), 367
(1992): Breathnach SM+, Adverse Drug Reactions and the Skin
Blackwell, Oxford, 292 (passim)
(1990): Siegel RD+, Chest 98, 507
(1982): Kukla LJ+, Cancer 50, 2283
Hair – gray
Nails
Nails – Beau’s lines (transverse nail bands)
(1994): Ben-Dyan D+, Acta Haematol 91, 89
Nails – dystrophy
(1984): Miller RAW, Arch Dermatol 120, 963
Nails – growth reduced
(1999): Susser WS+, JAmAcadDermatol40(3), 367
Nails – loss
(1999): Susser WS+, JAmAcadDermatol40(3), 367
(1986): Gonzalez FU+, Arch Dermatol 122, 974
Nails – onychodystrophy
(1999): Susser WS+, JAmAcadDermatol40(3), 367
(1985): Baran R, Ann Dermatol Venereol (French) 112, 463
Nails – onycholysis
(1999): Susser WS+, JAmAcadDermatol40(3), 367
(1998): Roussou P+, Acta Derm Venereol 78, 303
(1984): Snauwaert J+, Dermatologica 169, 172
Nails – pigmentation (banding)
Other
Anaphylactoid reactions/Anaphylaxis (10%)
Gangrene (digital)
(1998): Reiser M+, Eur J Clin Microbiol Infect Dis 17, 58
(1998): Surville-Barland J+, Eur J Dermatol 8, 221
(1993): Vayssairat M+, J Rheumatol 20, 921
Hypersensitivity (1–10%)
(2005): Lam MS, Ann Pharmacother 39(11), 1897 (1%)
(2001): Mutafoglu-Uysal K+, Turk J Pediatr 43(2), 172
(2001): Robinson JB+, Gynecol Oncol 82(3), 550
(1992): Weiss RB, Semin Oncol 19, 458
Inappropriate secretion of antidiuretic hormone (SIADH)
(1986): Hayes DF+, JSurgOncol32(3), 150
(1983): Ravikumar TS+, JSurgOncol24(3), 242
Injection-site phlebitis (1–10%)
Nephrotoxicity
(1992): Hansen SW, Dan Med Bull 39(5), 391 (with cisplatin &
vinblastine)
Neurotoxicity
(1992): Hansen SW, Dan Med Bull 39(5), 391 (with cisplatin &
vinblastine)